Table 2 Comparison of primary and secondary outcomes
From: The effect of dobutamine in sepsis: a propensity score matched analysis
Outcomes n (%) | Original patients (before matching) | PSM adjusted patients (after matching) | ||||||
|---|---|---|---|---|---|---|---|---|
Non-dobutamine group (N = 2165) | Dobutamine group (N = 121) | OR (95%CI) | P value | Non-dobutamine group (N = 334) | Dobutamine group (N = 118) | OR (95% CI) | P value | |
Hospital mortality | 754 (34.8%) | 72 (59.5%) | 2.75 (1.89–4.00) | 0.000 | 165 (49.4%) | 71 (60.2%) | 1.55 (1.01–2.37) | 0.044 |
MV use | 1312 (60.6%) | 108 (89.3%) | 5.40 (3.02–9.66) | 0.000 | 268 (80.2%) | 105 (89.0%) | 1.99 (1.05–3.76) | 0.032 |
RRT use | 208 (9.6%) | 28 (23.1%) | 2.83 (1.81–4.43) | 0.000 | 56 (16.8%) | 27 (22.9%) | 1.47 (0.88–2.47) | 0.140 |
Norepinephrine free days | 13.01 ± 13.74 | 11.47 ± 11.10 | Na | 0.255 | 12.68 ± 13.54 | 11.34. ± 11.20 | Na | 0.360 |
Cardiac arrhythmias | 912 (42.1%) | 68 (56.2%) | 1.76 (1.22–2.55) | 0.002 | 171 (51.2%) | 67(56.8%) | 1.25 (0.82–1.91) | 0.297 |
Duration of ICU stay (days) | 8.08 ± 9.97 | 11.77 ± 11.09 | Na | 0.000 | 10.20 ± 10.43 | 11.70 ± 11.18 | Na | 0.189 |
Duration of hospital stay (days) | 14.98 ± 15.15 | 14.98 ± 12.22 | Na | 0.997 | 15.54 ± 14.22 | 14.79 ± 12.29 | Na | 0.611 |